FindTrial
Sign In

Nivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis.

Nivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis. - Nivolumab plus Ipilimumab for PD-L1-positive advanced non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039784
Enrollment
Unknown
Registered
2020-03-14
Start date
2020-03-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PD-L1-positive previously untreated advanced non-small cell lung cancer

Interventions

None listed

Sponsors

Showa University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Advanced NSCLC with at least one measurable lesion No previous systemic anticaner treatment Performance status (PS) range of 0-1

Exclusion criteria

Exclusion criteria: Patients with EGFR-sensitive mutations wereexcluded in the case of histologically squamous cell carcinoma.

Design outcomes

Primary

MeasureTime frame
Progression free survival(PFS) in patients with PD-L1 expression levels of 1% or over—

Secondary

MeasureTime frame
Progression free survival(PFS) in patients with PD-L1 expression levels of 50% or over Overall survival(OS)in patients with PD-L1 expression levels of 1% or over Overall survival(OS) in patients with PD-L1 expression levels of 50% or over—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp+81337848532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026